FDA grants Amplyx's candidate drug APX001 orphan drug designated for treatment of cryptococcal disease

cryptococcal disease is an infectious disease of the lungs or central nervous system (brain or spinal cord) caused by the fungal cryptococcal (new cryptococcal or gat occultycocci) that is usually found and inhaled in the environmentrecently,http://
TheDevelopment Office of the u.SFDA(http://theof Rare DiseasesDrug (http:// has awarded thecompany's(http://the main candidate drug, APX001 Orphan Drug, for the treatment of cryptocococsisthe active part of APX01
APX001 is APX001A, which inhibits the highly conservative fungal enzyme Gwt1 and impairs the growth of major fungal pathogensIn a number of non-clinical studies, APX001 has shown broad-spectrum activity against common Candida genus and clostridium genus, including multi-drug-resistant strains, candida and rare hard-to-treat molds, as well as sickle genus, foot-inline bacteria genus and fungi from moldAPX001 is currently conducting a Phase 2 Clinical Trial (http:// to assess the effectiveness and safety of intravenous APX01 and oral APX001 in patients with first-line treatment of fungal infections After the FDA approved the New Drug (http:// Application (NDA) for Orphan Drug Designated Indications, the orphan drug designation will give APX001 a seven-year market monopoly in the United States 　　APX001 has previously been designated by orphan drugs to treat invasive candida, invasive clostridium disease, globlysporicos, and rare mold infections caused by the genus of foot-inline bacteria, sickle bacteria and mold ymes (including mold genus and root mold) in addition to orphan drug designations, the FDA has previously granted APX001 qualified infection Product (http:// (QIDP) designation for the treatment of cryptococcal disease, invasive candidacoccia, invasive clostridium disease and globlysporicos